Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder

被引:26
作者
Koran, LM
Pallanti, S
Paiva, RS
Quercioli, L
机构
[1] Stanford Univ, Med Ctr, Dept Psychiat & Behav Sci, OCD Clin, Stanford, CA 94305 USA
[2] Ist Neurosci, I-50137 Florence, Italy
关键词
intravenous; clomipramine; obsessive-compulsive; pulse loading;
D O I
10.1016/S0924-977X(97)00048-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: We compared gradually increased to pulse loaded doses of open-label, intravenous clomipramine (CMI) in patients with obsessive-compulsive disorder (OCD). Method: We treated adult outpatients with DSM-III-R OCD, who had no prior exposure to effective treatments. Pulse loading patients received 150 mg on day 1; 150 mg or 200 mg on day 2. Gradual dosing patients received 25 mg per day increased to 200 mg per day over 2 weeks and then continued for a mean of 43 days (n=40). After i.v. dosing, all patients received oral CMI; the total treatment period was 6 months. Results: Pulse loading completers (n=7) had a rapid, dramatic response (mean Y-BOCS score decrease of 32% five days after pulse-loading). At this point (day 7), completers in the gradual intravenous group (n=20) exhibited no mean change in Y-BOCS score. The pulse loading group reached both a 25% or greater and a 50% or greater decrease in Y-BOCS score statistically and clinically significantly faster than the gradual group. Conclusions: Pulse-loaded intravenous CMI for the treatment of OCD deserves further study. (C) 1998 Elsevier Science B.V./ECNP.
引用
收藏
页码:121 / 126
页数:6
相关论文
共 17 条
[1]  
ALARCON RD, 1993, J CLIN PSYCHOPHARM, V13, P210
[2]  
CAPSTICK N, 1971, PSYCHOSOMATICS, V12, P332
[3]  
DEVEAUGHGEISS J, 1991, ARCH GEN PSYCHIAT, V48, P730
[4]  
DEVEAUGHGEISS J, 1990, PSYCHOPHARMACOL BULL, V26, P54
[5]  
DEVEAUGHGEISS J, 1989, PSYCHOPHARMACOL BULL, V25, P36
[6]  
*DIAGN STAT MAN ME, 1987, DSM3R, P245
[7]   THE BIOAVAILABILITY OF ORAL AND PARENTERAL CHLORIMIPRAMINE (ANAFRANIL) [J].
EVANS, LEJ ;
BETT, JHN ;
COX, JR ;
DUBOIS, JP ;
VANHEES, T .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY, 1980, 4 (03) :293-302
[8]  
FALLON BA, 1992, J NEUROPSYCH CLIN N, V4, P70
[9]  
GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006
[10]  
Hamilton M., 1967, British Journal of Social and Clinical Psychology, V6, P278